Details of Drug Interaction | MecDDI

Drug General Information (ID: DDI5AFGUYN)
Drug Name			Carbamoylcholine (ophthalmic)		Drug Info		Rocuronium		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Ophthalmic Glaucoma Agents				Neuromuscular Blocking Agents
Structure

Mechanism of Carbamoylcholine (ophthalmic)-Rocuronium Interaction (Severity Level: Moderate)
Antagonize the effect of neuromuscular blocking agents Click to Show/Hide Mechanism Graph

Drug Name		Carbamoylcholine (ophthalmic)				Rocuronium
Mechanism		Anti-neuromuscular blocking effect Muscarinic acetylcholine receptor Agonist				Neuromuscular blocking agent Neuronal acetylcholine receptor Antagonist
Key Mechanism Factor 1
		Factor Name		Muscarinic acetylcholine receptor M				Structure Sequence
		Protein Family		G-protein coupled receptor 1 family
		Protein Function		The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover. Click to Show/Hide
Key Mechanism Factor 2
		Factor Name		Neuronal acetylcholine receptor				Structure Sequence
		Protein Family		Ligand-gated ion channel (TC 1.A.9) family
		Protein Function		After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. Click to Show/Hide
Mechanism Description		Antagonize the effect of Rocuronium when combined with Carbamoylcholine (ophthalmic)

Recommended Action
Management		The patient should be monitored for adequate neuromuscular blockade and the dosage adjusted, if necessary.

References
1	Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979): 199-255. [PMID: 376469]
2	Hardman JG, Limbird LE, Gilman AG, eds. "Goodman and Gilman's the Pharmacological Basis of Therapeutics. 10th ed." New York, NY: McGraw-Hill (2001):.